Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 11:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 355 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Powder Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia

NCT05021341
View directory record Official record
Conditions
Glycemia
Interventions
Berberine, Dihydroberberine 200, Dihydroberberine 100, Placebo
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Glycine vs Placebo for the Schizophrenia Prodrome

NCT00291226
View directory record Official record
Conditions
Schizophrenia Prodrome
Interventions
Glycine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 35 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin A to Treat Arm Tremor

NCT02207946
View directory record Official record
Conditions
Essential Tremor of the Upper Limbs
Interventions
IncobotulinumtoxinA, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 27, 2026, 11:43 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa

NCT03019406
View directory record Official record
Conditions
Glycogen Storage Disease Type II-Pompe's Disease
Interventions
Avalglucosidase alfa (GZ402666), Alglucosidase alfa (GZ419829)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
3
States / cities
Valhalla, New York • Durham, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Not applicable Interventional

L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients

NCT00587418
View directory record Official record
Conditions
Liver Transplant Recipients
Interventions
L-arginine, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study Evaluating the Digestibility of Serum-Derived Bovine Immunoglobulin Protein Isolate in Healthy Adults

NCT02017405
View directory record Official record
Conditions
Healthy
Interventions
Serum-derived bovine immunoglobulin protein isolate (SBI), Matching Placebo
Other
Lead sponsor
Entera Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Cary, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Not applicable Interventional

Protein Supplementation in Infants With Brain Injury

NCT01936246
View directory record Official record
Conditions
Perinatal Stroke, Hypoxic-ischemic Encephalopathy, White Matter Injury
Interventions
Increased protein
Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Days to 3 Weeks
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

NCT01125748
View directory record Official record
Conditions
Allergic Asthma
Interventions
Omalizumab, Placebo, Asthma therapies
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
17 Years to 70 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
100
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of Protein and Alkali Supplementation on Skeletal Muscle in Older Adults

NCT04048616
View directory record Official record
Conditions
Age-Related Sarcopenia, Muscle Loss
Interventions
whey protein isolate, potassium bicarbonate (KHCO3), microcrystalline cellulose, maltodextrin powder
Dietary Supplement · Other
Lead sponsor
Tufts University
Other
Eligibility
65 Years and older
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Phase 3 Interventional Results available

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

NCT02002884
View directory record Official record
Conditions
Cerebral Palsy, Spasticity
Interventions
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Not applicable Interventional

Adjunctive Glycine for Obsessive Compulsive Disorder

NCT00405535
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
glycine, placebo
Drug · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 27, 2026, 11:43 AM EDT
Recruiting Phase 2 Interventional

5-HTP and Creatine for Depression R33 Phase

NCT05895747
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low Dose 5-hydroxytryptophan, High Dose 5-hydroxytryptophan, Low Dose Creatine Monohydrate, High Dose Creatine Monohydrate, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Phase 3 Interventional

Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes

NCT00127634
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Human Insulin Inhalation Powder, Injectable Insulin, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
35
States / cities
Sacramento, California • Walnut Creek, California • Aurora, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 27, 2026, 11:43 AM EDT
Terminated Phase 1 Interventional

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

NCT03064854
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
PDR001, Cisplatin, Gemcitabine, Pemetrexed, Carboplatin, Paclitaxel, Canakinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Fayetteville, Arkansas • Santa Monica, California • Stanford, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Influence of Regular Beef Consumption and Protein Density of the Diet on Training-induced Gains in Muscle Strength and Performance in Healthy Adults

NCT03029975
View directory record Official record
Conditions
Aging
Interventions
Resistance Training Exercise, Beef Protein Consumption
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
40 Years to 64 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 27, 2026, 11:43 AM EDT
Not yet recruiting Not applicable Interventional

High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)

NCT07700030
View directory record Official record
Conditions
Weight Loss
Interventions
High protein diet, Resistance Training (RT) Programs
Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
30 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 27, 2026, 11:43 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

SOAR-2: Intervening in Obesity Through Reduction of Dietary Branched Chain Amino Acids

NCT04424537
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
Control diet, Low branched-chain amino acids(BCAA) diet, Low protein diet
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
30 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Phase 2 Interventional Results available

Use of Infliximab for the Treatment of Pemphigus Vulgaris

NCT00283712
View directory record Official record
Conditions
Pemphigus
Interventions
Infliximab, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Phase 1 Interventional

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan

NCT02030964
View directory record Official record
Conditions
Neuroblastoma
Interventions
DFMO, Celecoxib, Cyclophosphamide, Topotecan
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
2 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler

NCT01490762
View directory record Official record
Conditions
Healthy
Interventions
Technosphere Insulin Inhalation Powder using the Gen2C inhaler, Regular Human Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Phase 4 Interventional Results available

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

NCT01110200
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ADVAIR DISKUS 250/50 mg BID, SEREVENT 50 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 85 Years
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
74
States / cities
Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Not applicable Interventional Results available

Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS

NCT03717935
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions
Essential Amino Acid (EAA) Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 27, 2026, 11:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy and Affordable Protein Rich Foods for African Market

NCT02757508
View directory record Official record
Conditions
School Feeding Programs and Nutrition Supplements
Interventions
protein powder supplement, Vitamins/minerals
Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 9 Years
Enrollment
1,041 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 27, 2026, 11:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring

NCT07254364
View directory record Official record
Conditions
Insulin Response, Type 1 Diabetes
Interventions
Standardized meal 1
Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 11:43 AM EDT